Director/PDMR Shareholding

RNS Number : 1352N

e-Therapeutics plc

25 September 2012

 

e-Therapeutics plc ("e-Therapeutics" or "the Company")

Notification of Transactions of Directors, Persons Discharging Managerial  Responsibility or Connected Persons

The Company was advised on 24 September 2012 that Novotech Investment Limited (NIL), a company that Professor Malcolm Young (CEO) is a Director of and in which he has options to subscribe for ordinary shares, hadtransferred 410,059 ordinary shares of 0.1p each to a nominee company, Brewin Dolphin Nominees Limited. The transfer does not result in a change to Professor Young's total beneficial interest which remains the same at 20,620,482  shares representing 14.92% of the total voting rights (of which 10,310,241 shares are held by Professor Young and 10,310,241 shares are held by Professor Young's wife). Professor Young also has an indirect holding of a further 428,512 shares relating to interests that he holds in NIL and Novotech Syndicate LLP.

25 September 2012

Contacts

e-Therapeutics plc Tel: [phone]

Daniel Elger

Panmure Gordon (UK) Limited Tel: [phone]

Fred Walsh / Grishma Patel / Hannah Woodley

 

END

 

 

RDSLLFLEADIEFIF